Clinical pharmacology and medication-associated side effects: A review of second-generation antipsychotics for schizophrenia

Clinical Schizophrenia and Related Psychoses

Volumn 1, Issue 2, 2007, Pages 135-136

  Conley, Robert R ^a   Kelly, Deanna L ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Extrapyramidal Side Effects; Pharmacology; Prolactin; Second Generation Antipsychotics; Side Effects; Weight Gain

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CHOLESTEROL; CLOZAPINE; FLUPHENAZINE; GLUCOSE; HALOPERIDOL; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; TRIACYLGLYCEROL; ZIPRASIDONE;

ABDOMINAL PAIN; ACUTE DISEASE; AGITATION; AGRANULOCYTOSIS; AKATHISIA; AKINESIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ATHETOSIS; CARDIOMYOPATHY; CARDIOPULMONARY INSUFFICIENCY; CATARACT; CHOLESTEROL BLOOD LEVEL; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONSTIPATION; DIABETIC KETOACIDOSIS; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIAPHORESIS; DIARRHEA; DIZZINESS; DROWSINESS; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; DYSTONIA; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; FREE THYROXINE INDEX; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPOTENSION; INFECTION; INSOMNIA; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIA; KIDNEY FAILURE; METABOLIC DISORDER; MORBIDITY; MUSCLE HYPERTONIA; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PATIENT COMPLIANCE; PROLACTIN BLOOD LEVEL; PSEUDOPARKINSONISM; PSYCHOPHARMACOLOGY; QT PROLONGATION; RECEPTOR AFFINITY; REPRODUCTIVE TOXICITY; REVIEW; RHINITIS; RIGIDITY; SALIVATION; SCHIZOPHRENIA; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STIFF NECK; SYNCOPE; TACHYCARDIA; TARDIVE DYSKINESIA; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 65249124237     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.1.2.2     Document Type: Review

References (75)

1. Shen W W. A history of antipsychotic drug development. Compr Psychiatry 1999;40:407-414.
2. Casey DE. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995;10(Suppl 3):105-114.
3. Sedvall GC. Neurobiological correlates of acute neuroleptic treatment. Int Clin Psychopharmacol 1996;11(Suppl 2):41-46.
4. Soubrie P, Reisine TD, Glowinski J. Functional aspects of serotonin transmission in the basal ganglia: a review and an in vivo approach using the push-pull cannula technique. Neuroscience 1984;131:615-624.
5. IMS Health. Retail & Provider Perspective, May 2006.
6. Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmar C, et al. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry 2003;160:1405-1412.
7. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al; HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in frst-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160:1396-1404.
8. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: a systematic overview and meta-regression analysis. BMJ 2000;321:1371-1376.
9. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Efectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-1223.
10. Fleischhacker WW, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: infuence of side effects. Acta Psychiatr Scand 1994;89(Suppl 382):11-15.
11. Physicians' Desk Reference. 60th edition. Montvale, NJ: Medical Economics, 2006.
12. Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;27:1841-1845.
13. Klimke A, Klieser E. Sudden death afer intravenous application of lorazepam in a patient treated with clozapine. Am J Psychiatry 1994;151:780.
14. Schulte PF. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother 2006;40:683-688.
15. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996;124:57-73.
16. Conley RR, Tamminga CA, Kelly DL, Richardson C. Treatment-resistant schizophrenic patients respond to clozapine afer olanzapine non-response. Biol Psychiatry 1999;46:73-77.
17. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profle of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96.
18. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ter 1995;275:101-113.
19. Taylor DM. Aripiprazole: a review of its pharmacology and clinical use. Int J Clin Pract 2003;57:49-54.
20. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90:147-161.
21. Beasley CM, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K, et al. Randomized double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999;174:23-30.
22. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:414-425.
23. Tenback DE, van Harten PN, Sloof CJ, Belger MA, van Os J; SOHO Study Group. Efects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry 2005;66:1130-1133.
24. Llorca PM, Chereau I, Bayle FJ, Lancon C. Tardive dyskine-sias and antipsychotics: a review. Eur Psychiatry 2002;17:263-264.
25. Yovtcheva S P, Stanley-Tilt C, Moles JK. Reemergence of tardive dyskinesia afer discontinuation of clozapine treatment. Schizophr Res 2000;46:107-109.
26. Uzun O, Cansever A, Ozsahin A. A case of relapsed tardive dyskinesia due to clozapine dose reduction. Int Clin Psychopharmacol 2001;16:369-371.
27. Carof SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002;63(Suppl 4):12-19.
28. Davidson M, Harvey PD, Vervarcke J, Gagiano CA, De Hooge JD, Bray G, et al. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. Int J Geriatr Psychiatry 2000;15:506-514.
29. Jeste D V, Lacro J P, Bailey A, Rockwell E, Harris MJ, Caliguiri M P. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999;47:716-719.
30. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthizen P P. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 2004;65:696-701.
31. Nelson MW, Reynolds RR, Kelly DL, Conley RR. Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone. Clin Neuropharmacol 2003;26:297-298.
32. Duggal HS. Aripiprazole-induced improvement in tardive dyskinesia. Can J Psychiatry 2003;48:771-772.
33. Sharma A, Ramaswamy S, Dewan VK. Resolution of ziprasi-done-related tardive dyskinesia with a switch to aripiprazole. Prim Care Companion J Clin Psychiatry 2005;7:36.
34. Aronne LJ. Epidemiology, morbidity and treatment of overweight and obesity. J Clin Psychiatry 2001;62(Suppl 23):13-22.
35. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(Suppl 7):22-31.
36. Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer HJ, Fleischhacker W. Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995;5:437-440.
37. Nemerof CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997;58(Suppl 10):45-49.
38. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62:92-100.
39. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J P, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoafective disorder. Am J Psychiatry 2002;159:255-262.
40. Csernansky JG, Mahmoud R, Brenner R; Risperidone USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22.
41. Brecher M, Rak IW, Westhead EK, et al. Te long-term effect of quetiapine (Seroquel) monotherapy on weight in patients with schizophrenia. Int J Psychiatry in Clin Practice 2000;4:287-292.
42. Hirsch SR, Kissling W, Bauml J, Power A, O'Connor R. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002;63(6):516-523.
43. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, et al. Efcacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325-337.
44. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001;62(Suppl 27):15-26.
45. Ramaswamy K, Masand PS, Nasrallah HA. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. Ann Clin Psychiatry 2006;18:183-194.
46. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk fac- tors for new onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002;14:59-64.
47. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 1996;53:79-81.
48. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a fve-year naturalistic study. Am J Psychiatry 2000;157:975-981.
49. Sheitman BB, Bird PM, Binz W, Akinli L, Sanchez C. Olanzapine-induced elevation of plasma triglyceride levels. Am J Psychiatry 1999;156:1471-1472.
50. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999;60:767-770.
51. Koro CE, Fedder DO, Weiss S, Magder LS, L'Italien GJ, Krey-enbuhl J, et al. An assessment of the independent efects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59:1021-1026.
52. Meyer JM. Efects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001;62:27-34.
53. Kelly DL, Kreyenbuhl J, Love RC, Van-Duong Q, Conley RR. Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine. J Clin Psychiatry 2003;64:1133-1134.
54. Montes JM, Rodriquez JL, Balbo E, Sopelana P, Martin E, Soto JA, et al. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:383-388.
55. Spurling RD, Lamberti JS, Olsen D, Tu X, Tang W. Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. J Clin Psychiatry 2007;68:406-409.
56. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-1128.
57. Burns T, Floritti A, Holloway F, Malm U, Rossler W. Case management and assertive community treatment in Europe. Psychiatr Serv 2001;52(5):631-636.
58. Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic patients. J Nerv Ment Dis 1982;170(8):463-467.
59. Pollack MH, Reiter S, Hammerness P. Genitourinary and sexual adverse efects of psychotropic medication. Int J Psychiatry Med 1992;22:305-327.
60. Wilson CA. Pharmacological targets for the control of male and female sexual behaviour. In: Riley AJ, Peet M, Wilson C, editors. Sexual pharmacology. Oxford: Oxford Medical Pub-lications;1993:p.1-58.
61. Tran P V, Hamilton SH, Kuntz AJ, Potvin JH, Anderson SW, Beasley C Jr, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418.
62. Bobes J, Garc A-Portilla MP, Rejas J, Hernandez G, Garcia-Garcia M, et al. Frequency of sexual dysfunction and other reproductive side-efects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ter 2003;29:125-147.
63. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002;159:133-135.
64. Alzenberg D, Modai I, Landa A, Gil-Ad I, Weizman A. Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. J Clin Psychiatry 2001;62:541-544.
65. Kleinberg DL, Davis JM, De Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999; 19:57-61.
66. Mullen B, Brar JS, Vagnucci AH, Ganguli R. Frequency of sexual dysfunction in patients with schizophrenia on haloperidol, clozapine, or risperidone. Schizophr Res 2001; 48:155-158.
67. Crawford AMK, Beasley CM Jr, Tollefson GD. Te acute and long-term efect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997;26:41-54.
68. Arvanitis L, Miller B. Multiple fxed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Te Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42(4):233-246.
69. Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol 2006;21:529-532.
70. Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005;162:1010-1012.
71. Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V. Efects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004;184:503-508.
72. Jung DU, Conley RR, Kelly DL, Kim DW, Yoon SH, Jang JH, et al. Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry 2006;67:1391-1396.
73. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
74. Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, et al. Te Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull 2002;28:5-16.
75. Gupta J. Monitoring parameters for atypical antipsychoticsa review of the evidence. Central and Northwest London: National Health Service [accessed 2007 Feb 13]. Available from: www.ukppg.org.uk/atypical-monitoring-cw.pdf.